An antibody test for early detection if a person has a very high risk of developing an HPV-associated cancer of the oropharynx has been developed. In the U.S, cancer of the oropharynx has become increasingly common and the number of newly diagnosed cases has tripled over the past three decades. About 70% of these tumors are caused by infection with human papillomavirus (HPV) type 16.